CMSC: Consortium of Multiple Sclerosis Centers
Conference Coverage
MS drugs during pregnancy show no safety signals
Data on outcomes from cladribine, ocrelizumab, ofatumumab, and ozanimod during pregnancy showed no miscarriages or malformations above the general...
Conference Coverage
Multiple sclerosis has a misdiagnosis problem
Experts warn that false-negative diagnoses cause treatment delays, while false-positive diagnoses run the risk for potential harm from needless...
Conference Coverage
No apparent drug interaction with ozanimod and antidepressants
Patients with MS who are taking SSRIs or SNRIs had lower rates of hypertension and adverse events potentially related to serotonin than patients...
Conference Coverage
‘Strikingly positive’ effect of novel MS agent
Frexalimab is a novel second-generation monoclonal antibody designed to block the costimulatory CD40/CD40L cellular pathway.
Conference Coverage
MS relapse rates similar between anti-CD20 mAbs and switching to fumarates
Although overall health care encounters did not statistically differ between patients who switched from anti-CD20 monoclonal antibodies to...
Conference Coverage
Shingles infection rates higher in patients with MS
Even among patients with MS who had no baseline immunosuppression from therapy, rates of herpes zoster infection were significantly higher than...
Conference Coverage
Ozanimod for relapsing MS shows long-term safety, efficacy with age differences
Urinary tract infections and other treatment-emergent adverse events increased with age, but respiratory infections were more common among...
Conference Coverage
Multiple changes in NMOSD treatment for nonmedical reasons tied to poorer outcomes
“Our data highlight that aspects outside of therapeutic efficacy may be remarkably meaningful in the effective suppression of disease advancement...
Conference Coverage
Racial, ethnic disparities persist in access to MS care
Hispanic patients were significantly more likely to consistently report lower access to MS-specific care and feeling less heard by their health...
Conference Coverage
Long-term freedom from NMOSD relapse with satralizumab
At week 240 (4.6 years), 72% of satralizumab-treated patients were relapse-free, with 91% free from severe relapse.
Conference Coverage
Mindfulness-based stress reduction program benefits MS patients
Two separate programs showed significant improvements in participants’ stress, depressive and anxiety symptoms, self-awareness, and self-efficacy...
From the Journals
COVID vaccination in DMT-treated MS patients: New data
Conference Coverage
Risk of drug interactions is on the rise as MS drugs evolve
Newer medications pose more danger, pharmacist says, and require more awareness.
Conference Coverage
Consider the wider picture in relapsing remitting MS
The best medication for a patient may not have highest efficacy, one expert says.
Conference Coverage
MS and family planning: Bring it up at every office visit
It’s crucial to counsel women of child-bearing age about options and facts regarding pregnancy, neurologist says.